ALNY - Alnylam Pharmaceuticals Inc logo

Alnylam Pharmaceuticals Inc

ALNY

Alnylam Pharmaceuticals develops RNA interference-based therapeutics, offering treatments for conditions like hereditary amyloidosis, hypercholesterolemia, and hemophilia. Its pipeline includes drugs in advanced trials for various genetic and metabolic diseases.

βš•οΈ Healthcare NASDAQ Listed 2004 $ USD
$1,000 invested 20 years ago β†’$7,709today

Score Overview

1 Year
Score
Net Growth8x
Net TrendGrew
Net Income Consistencyβ€”
Rev Growth34.98%
Rev TrendGrew
Revenue Consistencyβ€”
5 Years
Score8.7
Net Growth419.44%
Net Trend80%
Net Income Consistencyβ€”
Rev Growth493.78%
Rev TrendEvery year
Revenue Consistencyβ€”
10 Years
Score
Net Growth8x
Net Trend60%
Net Income Consistency
Rev Growth106x
Rev Trend90%
Revenue Consistency
20 Years
Score5.2
Net Growth80x
Net Trend50%
Net Income Consistency
Rev Growth186x
Rev Trend70%
Revenue Consistency
All Time
Score
Net Growth85x
Net Trend50%
Net Income Consistency
Rev Growth1171x
Rev Trend73%
Revenue Consistency

Explore the 2021 public Archive ranking β†’

Where Alnylam Pharmaceuticals Inc has ranked, year by year

Measure
Fundamentals Window

Showing 10 years ranking history by HDB Score.

Has not reached the top 50 on HDB Score in any year we have ranked.

  • ALNY

2015: 94.1% Β· 2021: 96.8% Β· free through 2021 Β· longest runs

Net Income x Stock Price

Historical Returns

Historical Returns
PeriodPriceReturn
Last Price2026-11-17
$ 156.50β€”
1 Year2025-11-17
$ 460.54-66.02%
5 Years2021-11-17
$ 172.73-9.40%
10 Years2016-11-17
$ 46.36237.58%
20 Years2006-11-17
$ 20.307x
All Time2004-05-28
$ 6.0126x

Prices are split & dividend adjusted. All values are reported in USD.

Fundamental Data

Reported in USD

Year
TTM$ 5.01B$ 2.72B$ 3.58B
2025$ 3.71B$ 313M$ 2.90B
2024$ 2.24B-$ 278M$ 2.69B
2023$ 1.82B-$ 440M$ 2.43B
2022$ 1.03B-$ 1.13B$ 2.19B
2021$ 844M-$ 852M$ 2.43B
2020$ 492M-$ 858M$ 1.87B
2019$ 219M-$ 886M$ 1.53B
2018$ 74M-$ 761M$ 1.08B
2017$ 89M-$ 490M$ 1.70B
2016$ 47M-$ 410M$ 942M
2015$ 41M-$ 290M$ 1.08B
2014$ 50M-$ 360M$ 696M
2013$ 47M-$ 89M$ 245M
2012$ 66M-$ 106M$ 122M
2011$ 82M-$ 57M$ 146M
2010$ 100M-$ 43M$ 233M
2009$ 100M-$ 47M$ 281M
2008$ 96M-$ 26M$ 430M
2007$ 50M-$ 85M$ 389M
2006$ 26M-$ 34M$ 217M
2005$ 5M-$ 42M$ 80M
IPO2004$ 4M-$ 32M$ 46M
ALNY - Alnylam Pharmaceuticals Inc logo

Alnylam Pharmaceuticals Inc fundamental performance

Between 2020 and 2025, revenue grew from $ 492M to $ 3.71B and net income went from -$ 858M to $ 313M. Revenue increased in every one of those 5 years; net income in 4.

Between 2015 and 2025, revenue grew from $ 41M to $ 3.71B and net income went from -$ 290M to $ 313M. Revenue increased in 9 of those 10 years; net income in 6.

Alnylam Pharmaceuticals Inc currently holds a 20-year HDB Score of 5.2 out of 10. How the HDB Score is calculated.

Membership

Continue ALNY’s history

The public Archive runs through 2021. Membership adds recent and current rankings.

  • Recent and current rankings across 5,187 companies
  • Compare companies with the latest data
  • Track your research shortlist in a portfolio

$149 / year

or $19/month

Continue with Membership

30-day money-back guarantee.

Explore other companies